Trial · NCT01675661

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

NCT01675661, Phase 3, Completed, Medical University of South Carolina; results first posted 2017-03-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment. Trials, record NCT01675661. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01675661

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
NCT number: NCT01675661
Status: Completed
Phases: Phase 3
Enrollment: 302 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine, Placebo
First posted: 2012-08-30
Last updated: 2018-05-24
Results first posted: 2017-03-08

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Odds of Negative Urine Cannabinoid Tests During Treatment.	study weeks 2-13	The primary outcome is the abstinence rate over the 12 weeks of treatment. Abstinence is based on a weekly urine drug screen confirmed by central laboratory testing and defined as a negative cannabinoid result.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Odds of Negative Urine Cannabinoid Tests During Treatment.	study weeks 2-13	Intent to treat; all participants randomized	cannabis negative urine tests	NUMBER

Source ClinicalTrials.gov

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
The Odds of Negative Urine Cannabinoid Tests During Treatment.	NAC Plus CM	Study Week 2	25	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	Placebo Plus CM	Study Week 2	21	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	NAC Plus CM	Study Week 3	30	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	Placebo Plus CM	Study Week 3	22	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	NAC Plus CM	Study Week 4	33	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	Placebo Plus CM	Study Week 4	36	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	NAC Plus CM	Study Week 5	32	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	Placebo Plus CM	Study Week 5	33	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	NAC Plus CM	Study Week 6	32	cannabis negative urine tests
The Odds of Negative Urine Cannabinoid Tests During Treatment.	Placebo Plus CM	Study Week 6	30	cannabis negative urine tests

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	NAC Plus CM	153
Overall Study	STARTED	Placebo Plus CM	149
Overall Study	COMPLETED	NAC Plus CM	113
Overall Study	COMPLETED	Placebo Plus CM	103
Overall Study	NOT COMPLETED	NAC Plus CM	40
Overall Study	NOT COMPLETED	Placebo Plus CM	46

Source ClinicalTrials.gov

Adverse events106

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea	Gastrointestinal disorders	NAC Plus CM	7	153	7
other	Nausea	Gastrointestinal disorders	Placebo Plus CM	10	149	10
other	Diarrhea	Gastrointestinal disorders	NAC Plus CM	8	153	8
other	Diarrhea	Gastrointestinal disorders	Placebo Plus CM	8	149	8
other	Abdominal discomfort	Gastrointestinal disorders	NAC Plus CM	3	153	3
other	Abdominal discomfort	Gastrointestinal disorders	Placebo Plus CM	5	149	5
other	Dyspepsia	Gastrointestinal disorders	NAC Plus CM	3	153	3
other	Dyspepsia	Gastrointestinal disorders	Placebo Plus CM	1	149	1
other	Flatulence	Gastrointestinal disorders	NAC Plus CM	0	153	0
other	Flatulence	Gastrointestinal disorders	Placebo Plus CM	2	149	2

1 to 10 of 106Source ClinicalTrials.gov

See all 106 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	NAC Plus CM
Total, all-cause mortality	Placebo Plus CM
Total, other adverse events	NAC Plus CM	40	153
Total, other adverse events	Placebo Plus CM	45	149
Total, serious adverse events	NAC Plus CM	1	153
Total, serious adverse events	Placebo Plus CM	6	149

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
25179587	BACKGROUND	PubMed
28623823	DERIVED	PubMed
28847455	DERIVED	PubMed
31712969	DERIVED	PubMed
34197135	DERIVED	PubMed
35084903	DERIVED	PubMed

Grants7

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
UG1DA013727	Southern Consortium Node of the Clinical Trials Network	BARTH, KELLY S.; BRADY, KATHLEEN T.	MEDICAL UNIVERSITY OF SOUTH CAROLINA	NATIONAL INSTITUTE ON DRUG ABUSE	2015 to 2025	NIH RePORTER
U10DA013045	The National Drug Abuse Treatment Clinical Trials Network	LING, WALTER NMN	UNIVERSITY OF CALIFORNIA LOS ANGELES	NATIONAL INSTITUTE ON DRUG ABUSE	1999 to 2015	NIH RePORTER
U10DA013727	Southern Consortium Node of the Clinical Trials Network	BRADY, KATHLEEN T.	MEDICAL UNIVERSITY OF SOUTH CAROLINA	NATIONAL INSTITUTE ON DRUG ABUSE	2000 to 2015	NIH RePORTER
U10DA013732	Clinical Trials Network, Ohio Valley Node U10DA013732	WINHUSEN, T JOHN	UNIVERSITY OF CINCINNATI	NATIONAL INSTITUTE ON DRUG ABUSE	2000 to 2015	NIH RePORTER
U10DA015815	Western States Node of the National Drug Abuse Treatment Clinical Trials Network	SORENSEN, JAMES L; MCCARTY, DENNIS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	NATIONAL INSTITUTE ON DRUG ABUSE	2002 to 2015	NIH RePORTER
U10DA015831	The National Drug Abuse Treatment Clinical Trials Network (U10)	WEISS, ROGER D.; CARROLL, KATHLEEN M.	MCLEAN HOSPITAL	NATIONAL INSTITUTE ON DRUG ABUSE	2002 to 2015	NIH RePORTER
U10DA020024	Clinical Trials Network: The Texas Node	TRIVEDI, MADHUKAR H.	UT SOUTHWESTERN MEDICAL CENTER	NATIONAL INSTITUTE ON DRUG ABUSE	2005 to 2015	NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
NAC Plus CM vs Placebo Plus CM: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01675661

GET https://conductscience.org/api/trials/v1/NCT01675661/results?page=2

API reference For AI assistants